Atlas Trials

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Clinical trial NCT01081431 · COMPLETED

Trial details

NCT number
NCT01081431
Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2010-03-26
Primary completion
2018-05-24
Enrollment
91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.